Ignite Creation Date:
2025-12-24 @ 11:53 PM
Ignite Modification Date:
2025-12-25 @ 9:49 PM
Study NCT ID:
NCT01968551
Status:
COMPLETED
Last Update Posted:
2018-11-16
First Post:
2013-09-26
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults
Sponsor:
Gilead Sciences
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-09-03
Start Date Type:
ACTUAL
Primary Completion Date:
2015-07-21
Primary Completion Date Type:
ACTUAL
Completion Date:
2016-07-09
Completion Date Type:
ACTUAL
First Submit Date:
2013-09-26
First Submit QC Date:
None
Study First Post Date:
2013-10-24
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2016-07-20
Results First Submit QC Date:
None
Results First Post Date:
2016-11-01
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2015-05-06
Disp First Post Date Type:
ESTIMATED
Last Update Submit Date:
2018-10-19
Last Update Post Date:
2018-11-16
Last Update Post Date Type:
ACTUAL